Aclaris Therapeutics Inc (NASDAQ:ACRS)’s traded shares stood at 0.63 million during the latest session, with the company’s beta value hitting 0.59. At the last check today, the stock’s price was $1.12, to imply an increase of 3.69% or $0.04 in intraday trading. The ACRS share’s 52-week high remains $5.17, putting it -361.61% down since that peak but still an impressive 15.18% since price per share fell to its 52-week low of $0.95. The company has a valuation of $120.86M, with an average of 0.86 million shares in intraday trading volume over the past 10 days and average of 912.45K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Aclaris Therapeutics Inc (ACRS), translating to a mean rating of 1.40. Of 4 analyst(s) looking at the stock, 1 analyst(s) give ACRS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy.
Aclaris Therapeutics Inc (NASDAQ:ACRS) trade information
After registering a 3.69% upside in the latest session, Aclaris Therapeutics Inc (ACRS) has traded red over the past five days. The 5-day price performance for the stock is -20.01%, and -28.21% over 30 days. With these gigs, the year-to-date price performance is -54.84%. Short interest in Aclaris Therapeutics Inc (NASDAQ:ACRS) saw shorts transact 6.03 million shares and set a 7.26 days time to cover.
The extremes give us $3 and $8 for target low and target high price respectively. As such, ACRS has been trading -614.29% off suggested target high and -167.86% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 15.24% for the past 5-year period. While 2025 is set for a 60.09% return in earnings, projections for the next 5 years are at 19.73% annually.
ACRS Dividends
Aclaris Therapeutics Inc has its next earnings report out on 2025-Feb-26. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Aclaris Therapeutics Inc (NASDAQ:ACRS)’s Major holders
Aclaris Therapeutics Inc insiders hold 2.66% of total outstanding shares, with institutional holders owning 82.41% of the shares at 84.66% float percentage. In total, 82.41% institutions holds shares in the company, led by BML CAPITAL MANAGEMENT, LLC. As of 2024-06-30, the company held over 12.99 million shares (or 18.2184% of shares), all amounting to roughly $14.29 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 4.69 million shares, or about 6.5952% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $5.16 million.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Aclaris Therapeutics Inc (ACRS) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 2.12 shares. This is just over 1.96% of the total shares, with a market valuation of $2.36 million. Data from the same date shows that the other fund manager holds a little less at 968.7, or 0.90% of the shares, all valued at about 1.08 million.
